BFO
VRTX icon

Boston Family Office’s Vertex Pharmaceuticals VRTX Stock Holding History

Boston Family Office’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$619K Buy
1,246
+130
+12% +$57.6K 0.04% 204
2026
Q1 		$498K Buy
1,116
+370
+50% +$173K 0.03% 222
2025
Q4 		$338K Hold
746
– – 0.02% 247
2025
Q3 		$292K Sell
746
-50
-6% -$20.9K 0.02% 251
2025
Q2 		$354K Buy
796
+345
+76% +$159K 0.02% 227
2025
Q1 		$219K Sell
451
-100
-18% -$46.6K 0.02% 267
2024
Q4 		$222K Sell
551
-15
-3% -$6.95K 0.02% 261
2024
Q3 		$263K Buy
+566
New +$272K 0.02% 244

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Boston Family Office's VRTX Position: Q2 2026 in Review

Boston Family Office increased its Vertex Pharmaceuticals (VRTX) stake by 12% in Q2 2026, buying an estimated $57.6K and bringing the position to 1,246 shares worth $619K. The position accounts for 0.04% of the portfolio, ranked #204.

Boston Family Office first reported a position in VRTX in Q3 2024 and has held it in 8 quarters since. 1,759 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

  • Boston Family Office held 1,246 shares of Vertex Pharmaceuticals worth $619K as of Q2 2026.
  • Boston Family Office bought 130 Vertex Pharmaceuticals shares in Q2 2026, an estimated $57.6K.
  • Vertex Pharmaceuticals made up 0.04% of Boston Family Office's portfolio in Q2 2026, its #204 holding.
  • Boston Family Office first reported a position in Vertex Pharmaceuticals in Q3 2024 and has held it in 8 quarters since.
  • 1,759 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Boston Family Office's 13F filing for Q2 2026, filed 12 Aug 2026.